What is the duration of effect for a perseris injection?

What determines how long Perseris lasts after an injection?

Perseris is an extended-release risperidone injection designed to release the medication steadily over one month. The formulation uses a polymer matrix that slowly degrades, maintaining therapeutic plasma levels for approximately 30 days after each subcutaneous dose.

How long do the clinical effects last?

Patients typically receive the injection once every 28 days. The antipsychotic effect remains consistent across the dosing interval because plasma concentrations stay above the minimum effective threshold for the full 30 days. Any noticeable change in symptoms usually occurs only after the drug levels begin to decline near the end of the month.

What happens if the next injection is delayed?

Missing the scheduled 28-day dose by a few days can allow risperidone levels to drop below therapeutic range, increasing the risk of symptom return. Guidelines recommend administering the next injection within seven days of the scheduled date; beyond that window, clinicians may consider a supplemental oral risperidone dose to bridge the gap until steady state is restored.

Why do some patients feel the effects wear off sooner?

Individual metabolism, injection-site fat thickness, and body mass can affect release kinetics. In patients with higher body mass index, absorption can be slightly slower, occasionally leading to a perception that the medication effect diminishes before the next scheduled dose. No dosage adjustment is required, but monitoring for early symptom recurrence is advised.

How does Perseris compare with other long-acting injectable antipsychotics?

Invega Sustenna requires monthly dosing but uses a different salt and route. Abilify Maintena and Aristada offer one-month or longer intervals with intramuscular administration. Perseris remains the only risperidone option given subcutaneously once monthly, offering a needle-size and administration-site alternative for patients who tolerate intramuscular injections poorly.

When does the patent for Perseris expire?

The primary U.S. composition-of-matter patent for the risperidone extended-release formulation expires in 2031, with additional method-of-use and formulation patents extending protection into the mid-2030s. Generic subcutaneous risperidone long-acting injectables are therefore not expected before 2032 at the earliest.

Who manufactures Perseris?

Indivior manufactures and markets Perseris. The company also produces the monthly buprenorphine injection Sublocade using a similar polymer-delivery platform.